This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Digna Biotech, S.L.

Drug Names(s): P-17, NAFB002

Description: NAFB002 (P17) is a synthetic peptide of 15 amino acids that inhibits TGF-beta 1.

Deal Structure: Digna and Flamel
In June 2011, Flamel and Digna announced that the two companies entered into a joint development agreement for the pre-clinical and clinical development of P17.

In July 2013, Flamel terminated its licensing agreement with Digna related to P144.

P17 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug